Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer

Molecular portraits of human breast tumours

Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551 · see citing works

The nuclear receptor superfamily: the second decade

Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964 · see citing works

Molecular basis of agonism and antagonism in the oestrogen receptor

Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355 · see citing works

Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · see citing works

Metastatic Behavior of Breast Cancer Subtypes

Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9820 · Cited by 2,262 · see citing works

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

Prat, A., Parker, J. S., Karginova, O. A., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,164 · see citing works

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964 · see citing works

Nuclear Receptor Coregulators: Cellular and Molecular Biology

McKenna, N. J., Lanz, R. B., & O’Malley, B. W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0366 · Cited by 1,905 · see citing works

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

† (2015) · The Lancet · doi:10.1016/s0140-6736(15)61074-1 · Cited by 1,523 · see citing works

Tamoxifen in the Treatment of Breast Cancer

Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,327 · see citing works

Biological determinants of endocrine resistance in breast cancer

Musgrove, E. A., & Sutherland, R. L. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2713 · Cited by 1,254 · see citing works

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

Toy, W., Shen, Y., Won, H. H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K. P., Fanning, S. W., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,252 · see citing works

The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer

Kumar, V., & Chambon, P. (1988) · Cell · doi:10.1016/0092-8674(88)90017-7 · Cited by 1,240 · see citing works

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

Shou, J., Massarweh, S., Osborne, C., Wakeling, A., Ali, S., Weiss, H., & Schiff, R. (2004) · Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,236 · see citing works

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145 · see citing works

Untitled work

(1991) · PubMed · Cited by 1,101 · see citing works

Estrogen receptor pathways to AP-1.

Kushner, P., Agard, D., Greene, G., Scanlan, T., Shiau, A., Uht, R., & Webb, P. (2000) · Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00108-4 · Cited by 953 · see citing works

Overcoming Endocrine Resistance in Breast Cancer

Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927 · see citing works

Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α

Campbell, R., Bhat-Nakshatri, P., Patel, N., Constantinidou, D., Ali, S., & Nakshatri, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010840200 · Cited by 880 · see citing works

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.

Osborne, C., Bardou, V., Hopp, T. A., Chamness, G., Hilsenbeck, S., Fuqua, S., Wong, J., Allred, D., Clark, G., & Schiff, R. (2003) · Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.353 · Cited by 831 · see citing works

Treatment of Breast Cancer

Hortobágyi, G. N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810013391407 · Cited by 782 · see citing works

Cloning of the human estrogen receptor cDNA.

Walter, P., Green, S., Greene, G. L., Krust, A., Bornert, J., Jeltsch, J., Staub, A., Jensen, E. Ø., Scrace, G., & Waterfield, M. D. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.23.7889 · Cited by 731 · see citing works

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer

Jeselsohn, R. M., Buchwalter, G., Angelis, C. D., Brown, M. A., & Schiff, R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.117 · Cited by 718 · see citing works

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer

Jeselsohn, R., Yelensky, R., Buchwalter, G., Frampton, G., Meric-Bernstam, F., Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Perez-Fidalgo, J. A., Cristofanilli, M., Gómez, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2332 · Cited by 674 · see citing works

Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.

Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T.-M., Schiff, R., Del-Rio, A. L., Ricote, M., Ngo, S., Gemsch, J., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.2920 · Cited by 660 · see citing works

Mechanisms of tamoxifen resistance

Ring, A., & Dowsett, M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00776 · Cited by 651 · see citing works

Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts

Li, S., Shen, D., Shao, J., Crowder, R. J., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.022 · Cited by 623 · see citing works

Estrogen Signaling Multiple Pathways to Impact Gene Transcription

Marino, M., Galluzzo, P., & Ascenzi, P. (2006) · Current Genomics · doi:10.2174/138920206779315737 · Cited by 618 · see citing works

Risk of endometrial cancer after tamoxifen treatment of breast cancer

van Leeuwen, F. E., van den Belt‐Dusebout, A. W., Leeuwen, F. E. V., Benraadt, J., Diepenhorst, F. W., van Tinteren, H., Coebergh, J. W. W., Kiemeney, L. A. L. M., Gimbrère, C. H. F., Otter, R., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92692-1 · Cited by 566 · see citing works

Estrogen receptor alpha and beta in health and disease

Jia, M., Dahlman‐Wright, K., & Gustafsson, J.-Α. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.04.008 · Cited by 543 · see citing works

Risk and prognosis of endometrial cancer after tamoxifen for breast cancer

Bergman, L., Beelen, M. L., Gallee, M. P. W., Hollema, H., Benraadt, J., & van Leeuwen, F. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02677-5 · Cited by 541 · see citing works

The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling

Dauvois, S., White, R., & Parker, M. G. (1993) · Journal of Cell Science · doi:10.1242/jcs.106.4.1377 · Cited by 522 · see citing works

Structure–function relationship of estrogen receptor α and β: Impact on human health

Ascenzi, P., Bocedi, A., & Marino, M. (2006) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.07.001 · Cited by 503 · see citing works

Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase

Gutierrez, M. C., DETRE, S. I., Johnston, S. R. D., Mohsin, S. K., Shou, J., Allred, D. C., Schiff, R., Osborne, C. K., & Dowsett, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.172 · Cited by 488 · see citing works

Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells.

Ottaviano, Y. L., Issa, J. J., Parl, F. F., Smith, H. S., Baylin, S. B., & Davidson, N. E. (1994) · PubMed · Cited by 481 · see citing works

Estrogen Receptor α Rapidly Activates the IGF-1 Receptor Pathway

Kahlert, S., Nuedling, S., van Eickels, M., Vetter, H., Meyer, R., & Grohé, C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m910345199 · Cited by 474 · see citing works

Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.

Patel, H., & Bihani, T. (2017) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 423 · see citing works

Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.

Yang, X., Phillips, D. L., Ferguson, A. T., Nelson, W. G., Herman, J. G., & Davidson, N. E. (2001) · PubMed · Cited by 419 · see citing works

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action

Osborne, C. K., Wakeling, A., & Nicholson, R. I. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601629 · Cited by 414 · see citing works

Aromatase, aromatase inhibitors, and breast cancer

Chumsri, S., Howes, T., Bao, T., Sabnis, G., & Brodie, A. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.02.001 · Cited by 401 · see citing works

FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent

Stenoien, D. L., Patel, K. N., Mancini, M. G., Dutertre, M., Smith, C. L., O’Malley, B. W., & Mancini, M. A. (2000) · Nature Cell Biology · doi:10.1038/35050515 · Cited by 396 · see citing works

Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization.

Fawell, S. E., White, R., Hoare, S., Sydenham, M. A., Pagé, M., & Parker, M. G. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6883 · Cited by 395 · see citing works

Comparison of the Effects of a Pure Steroidal antiestrogen With Those of Tamoxifen in a Model of Human Breast Cancer

Osborne, C. K., Coronado, E. B., Hilsenbeck, S. G., McCue, B. L., Wakeling, A. E., McClelland, R. A., Manning, D. L., & Nicholson, R. I. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.10.746 · Cited by 361 · see citing works

Endocrine resistance in breast cancer – An overview and update

Clarke, R. C., Tyson, J. J., & Dixon, J. M. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.035 · Cited by 356 · see citing works

Regulation of Estrogen Rapid Signaling through Arginine Methylation by PRMT1

Romancer, M. L., Treilleux, I., Leconte, N., Robin-Lespinasse, Y., Sentis, S., Bouchekioua‐Bouzaghou, K., Goddard‐Léon, S., Gobert, S., & Corbo, L. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.05.025 · Cited by 324 · see citing works

Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation

Fanning, S. W., Mayne, C. G., Dharmarajan, V., Carlson, K. E., Martin, T. A., Novick, S. J., Toy, W., Green, B., Panchamukhi, S., Katzenellenbogen, B. S., et al. (2016) · eLife · doi:10.7554/elife.12792 · Cited by 317 · see citing works

First-Pass Metabolism via UDP-Glucuronosyltransferase: a Barrier to Oral Bioavailability of Phenolics

Wu, B., Kulkarni, K. H., Basu, S., Zhang, S., & Hu, M. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22568 · Cited by 311 · see citing works

Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer

Goss, P. E., & Strasser, K. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.881 · Cited by 297 · see citing works

Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)

Hu, J., Hu, B., Wang, M., Xu, F., Miao, B., Yang, C., Wang, M., Liu, Z., Hayes, D. F., Chinnaswamy, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01572 · Cited by 286 · see citing works

An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer.

Zhang, Q., Borg, Å., Wolf, D. M., Oesterreich, S., & Fuqua, S. A. W. (1997) · PubMed · Cited by 286 · see citing works

Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.

Pink, J. J., & Jordan, V. C. (1996) · PubMed · Cited by 282 · see citing works

Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations

Jeselsohn, R. M., Bergholz, J. S., Pun, M. J., Cornwell, M., Liu, W., Nardone, A., Xiao, T., Li, W., Qiu, X., Buchwalter, G., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.004 · Cited by 278 · see citing works

Pathways to tamoxifen resistance

Riggins, R. B., Schrecengost, R. S., Guerrero, M. S., & Bouton, A. H. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.03.016 · Cited by 277 · see citing works

Tamoxifen, Raloxifene, and the Prevention of Breast Cancer*

Jordan, V. C., & Morrow, M. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0368 · Cited by 260 · see citing works

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts

Lai, A. G., Kahraman, M., Govek, S. P., Nagasawa, J. Y., Bonnefous, C., Julien, J., Douglas, K. L., Sensintaffar, J., Lu, N., Lee, K., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00054 · Cited by 253 · see citing works

Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors.

Lapidus, R. G., Ferguson, A. T., Ottaviano, Y. L., Parl, F. F., Smith, H. S., Weitzman, S. A., Baylin, S. B., Issa, J. J., & Davidson, N. E. (1996) · PubMed · Cited by 250 · see citing works

Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer

Juric, D., Jankú, F., Rodon, J. A., Burris, H. A., Mayer, I. A., Schüler, M., Seggewiß-Bernhardt, R., Gil-Martín, M., Middleton, M. R., Baselga, J. M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4475 · Cited by 247 · see citing works

ICI 182,780, a new antioestrogen with clinical potential

Wakeling, A. E., & Bowler, J. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90204-v · Cited by 246 · see citing works

Structural Basis for an Unexpected Mode of SERM-Mediated ER Antagonism

Wu, Y.-L., Yang, X., Ren, Z. M., McDonnell, D. P., Norris, J. D., Willson, T. M., & Greene, G. L. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.014 · Cited by 236 · see citing works

Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer

van Kruchten, M., de Vries, E. G. E., Glaudemans, A. W. J. M., van Lanschot, M. C. J., van Faassen, M., Kema, I. P., Brown, M., Schröder, C. P., de Vries, E. F., & Hospers, G. A. P. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0697 · Cited by 229 · see citing works

Efficacy of PI3K inhibitors in advanced breast cancer

Verret, B., Cortes, J., Bachelot, T., Andre, F., & Arnedos, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz381 · Cited by 221 · see citing works

Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility

Guan, J., Zhou, W. J., Hafner, M. A., Blake, R. A., Chalouni, C. M., Chen, I. P., Bruyn, T. D., Giltnane, J. M., Hartman, S. J., Heidersbach, A. J., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.026 · Cited by 216 · see citing works

Novel antioestrogens without partial agonist activity

Wakeling, A. E., & Bowler, J. (1988) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(88)90014-3 · Cited by 215 · see citing works

The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer

Fabian, C. J. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01587.x · Cited by 214 · see citing works

Oxidative Stress and AP-1 Activity in Tamoxifen-Resistant Breast Tumors In Vivo

Schiff, R. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.23.1926 · Cited by 211 · see citing works

Tamoxifen Resistance in Breast Cancer

Chang, M.-S. (2012) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2012.20.3.256 · Cited by 205 · see citing works

Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer

Zhou, Y., Yau, C. S. F., Gray, J. W., Chew, K., Dairkee, S. H., Moore, D. H., Eppenberger, U., Eppenberger‐Castori, S., & Benz, C. C. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-59 · Cited by 203 · see citing works

The Mechanism of ICI 164,384 Antiestrogenieity Involves Rapid Loss of Estrogen Receptor in Uterine Tissue

Gibson, M. K., NEMMERS, L. A., Beckman, W. C., Davis, V. L., Curtis, S. W., & Korach, K. S. (1991) · Endocrinology · doi:10.1210/endo-129-4-2000 · Cited by 198 · see citing works

Measurement of steroid hormone receptors in breast cancer patients on tamoxifen

Encarnaci�n, C. A., Ciocca, D. R., McGuire, W. L., Clark, G. M., Fuqua, S. A. W., & Osborne, C. K. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00665801 · Cited by 194 · see citing works

Estrogen-Induced c-fos Protooncogene Expression in MCF-7 Human Breast Cancer Cells: Role of Estrogen Receptor Sp1 Complex Formation*

Duan, R., Porter, W. W., & Safe, S. H. (1998) · Endocrinology · doi:10.1210/endo.139.4.5870 · Cited by 192 · see citing works

Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer

McDonnell, D. P., Wardell, S. E., & Norris, J. D. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00760 · Cited by 178 · see citing works

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1 -Mutant Breast Tumors in Preclinical Models

Weir, H. M., Bradbury, R. H., Lawson, M., Rabow, A. A., Buttar, D., Callis, R. J., Curwen, J., de Almeida, C., Ballard, P. G., Hulse, M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2357 · Cited by 178 · see citing works

Fulvestrant (ICI 182,780)-dependent Interacting Proteins Mediate Immobilization and Degradation of Estrogen Receptor-α

Long, X., & Nephew, K. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510809200 · Cited by 170 · see citing works

Optimization of a Novel Binding Motif to ( E )-3-(3,5-Difluoro-4-((1 R ,3 R )-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1 H -pyrido[3,4- b ]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist

Savi, C. D., Bradbury, R. H., Rabow, A. A., Norman, R. A., de Almeida, C., Andrews, D. M., Ballard, P. G., Buttar, D., Callis, R. J., Currie, G. S., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00984 · Cited by 169 · see citing works

Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models

Bihani, T., Patel, H., Arlt, H., Tao, N., Jiang, H., Brown, J. L., Purandare, D. M., Hattersley, G., & Garner, F. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2561 · Cited by 169 · see citing works

Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models

Bahreini, A., Li, Z., Wang, P., Levine, K. M., Tasdemir, N., Cao, L., Weir, H. M., Puhalla, S. L., Davidson, N. E., Stern, A. M., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0851-4 · Cited by 162 · see citing works

RAD1901

Garner, F., Shomali, M., Paquin, D., Lyttle, C. R., & Hattersley, G. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000271 · Cited by 162 · see citing works

Biology and mode of action of pure antioestrogens.

Wakeling, A. E., & Bowler, J. (1988) · PubMed · doi:10.1016/0022-4731(88)90086-6 · Cited by 150 · see citing works

3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats

Willson, T. M., Henke, B. R., Momtahen, T. M., Charifson, P. S., Batchelor, K. W., Lubahn, D. B., Moore, L. B., Oliver, B. B., Sauls, H. R., Triantafillou, J. A., et al. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00037a002 · Cited by 146 · see citing works

Endocrine treatment in breast cancer: Cure, resistance and beyond

Tryfonidis, K., Zardavas, D., Katzenellenbogen, B. S., & Piccart, M. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.08.008 · Cited by 142 · see citing works

Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer

Tria, G. S., Abrams, T. J., Baird, J., Burks, H. E., Firestone, B., Gaither, L. A., Hamann, L. G., He, G., Kirby, C. A., Kim, S., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01682 · Cited by 134 · see citing works

Adverse Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer with Cyclin D1 Gene Amplification

Jirström, K., Stendahl, M., Rydén, L., Kronblad, Å., Bendahl, P.-O., Stål, O., Landberg, G., & Groups., T. S. S. A. S. S. B. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0746 · Cited by 133 · see citing works

Action of ?pure? antiestrogens in inhibiting estrogen receptor action

Parker, M. G. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00689686 · Cited by 131 · see citing works

The History and Mechanism of Action of Fulvestrant

Carlson, R. W. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.s.008 · Cited by 130 · see citing works

Studies on the mechanism of action of the nonsteroidal antioestrogen tamoxifen (I.C.I. 46,474) in the rat

Jordan, V. C., DIX, C. J., Rowsby, L., & Prestwich, G. (1977) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(77)90066-1 · Cited by 129 · see citing works

Understanding the genotoxicity of tamoxifen?

Phillips, D. H. (2001) · Carcinogenesis · doi:10.1093/carcin/22.6.839 · Cited by 125 · see citing works

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

Joseph, J. D., Darimont, B. D., Zhou, W. J., Arrazate, A., Young, A. E., Ingalla, E., Walter, K., Blake, R. A., Nonomiya, J., Guan, Z., et al. (2016) · eLife · doi:10.7554/elife.15828 · Cited by 122 · see citing works

New biospecific adsorbents for the purification of estradiol receptor.

Bucourt, R., Vignau, M., & TORELLI, V. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34385-5 · Cited by 121 · see citing works

Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader

Wardell, S. E., Nelson, E. R., Chao, C., Alley, H. M., & McDonnell, D. P. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0287 · Cited by 118 · see citing works

RU 58 668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice

Velde, P. V. D., Nique, F., Bouchoux, F., Brémaud, J., HAMEAU, M., Lucas, D., Moratille, C., Viet, S., Philibert, D., & Teutsch, G. (1994) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(94)90144-9 · Cited by 115 · see citing works

Estrogen Receptor-α Hinge-Region Lysines 302 and 303 Regulate Receptor Degradation by the Proteasome

Berry, N. B., Fan, M., & Nephew, K. P. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0449 · Cited by 112 · see citing works

Biological mechanisms and clinical implications of endocrine resistance in breast cancer.

Giuliano, M., Schiff, R., Osborne, C., & Trivedi, M. V. (2011) · Breast · doi:10.1016/s0960-9776(11)70293-4 · Cited by 111 · see citing works

Acquired resistance to aromatase inhibitors: where we stand!

Augusto, T. V., Correia‐da‐Silva, G., Rodrigues, C., Teixeira, N. A. A., & Amaral, C. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0425 · Cited by 109 · see citing works

Novel Mechanisms of Resistance to Endocrine Therapy: Genomic and Nongenomic Considerations

Gururaj, A. E., Rayala, S. K., Vadlamudi, R. K., & Kumar, R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2110 · Cited by 109 · see citing works

Requirements for estrogen receptor α membrane localization and function

Evinger, A. J., & Levin, E. (2005) · Steroids · doi:10.1016/j.steroids.2005.02.015 · Cited by 108 · see citing works

Aromatase inhibitors and their application in breast cancer treatment⋆

Brodie, A. M. H. (2000) · Steroids · doi:10.1016/s0039-128x(99)00104-x · Cited by 106 · see citing works

Nuclear Receptors, Coregulators, Ligands, and Selective Receptor Modulators

McKenna, N. J., & O’Malley, B. W. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03997.x · Cited by 96 · see citing works

Overexpression, Purification, and Crystal Structure of Native ERα LBD

Eiler, S., Gangloff, M., Duclaud, S., Moras, D., & Ruff, M. (2001) · Protein Expression and Purification · doi:10.1006/prep.2001.1409 · Cited by 92 · see citing works

Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy

Rudas, M., Lehnert, M., Huynh, A. T., Jakesz, R., Singer, C., Lax, S., Schippinger, W., Dietze, O., Greil, R., Stiglbauer, W., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4122 · Cited by 91 · see citing works

FDA Drug Approval Summaries: Fulvestrant

Bross, P. F., Cohen, M. H., Williams, G. A., & Pazdur, R. (2002) · The Oncologist · doi:10.1634/theoncologist.7-6-477 · Cited by 91 · see citing works

Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer

El‐Ahmad, Y., Tabart, M., Halley, F., Certal, V., Thompson, F., Filoche-Rommé, B., Gruss-Leleu, F., Muller, C., Brollo, M., Fabien, L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01293 · Cited by 90 · see citing works

Estrogen Receptors in Target Tissues

Jensen, E. V., Jacobson, H. I., Flesher, J. W., Saha, N., Gupta, G. N., Smith, S. B., COLUCCI, V., SHIPLACOFF, D., Neumann, H. G., DeSombre, E. R., et al. (1966) · Elsevier eBooks · doi:10.1016/b978-1-4832-2903-4.50009-x · Cited by 90 · see citing works

Estrogen Receptor Modulators: Identification and Structure−Activity Relationships of Potent ERα-Selective Tetrahydroisoquinoline Ligands

Renaud, J., Bischoff, S. F., Buhl, T., Floersheim, P., Fournier, B., Halleux, C. M., Kallen, J. A., Keller, H., Schlaeppi, J.-M., & Stark, W. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030086h · Cited by 89 · see citing works

Use of pure antioestrogens to elucidate the mode of action of oestrogens

Wakeling, A. E. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)00528-t · Cited by 88 · see citing works

Characterization of New Estrogen Receptor Destabilizing Compounds: Effects on Estrogen-Sensitive and Tamoxifen-Resistant Breast Cancer

Hoffmann, J., Bohlmann, R., Heinrich, N., Hofmeister, H., Kroll, J., Künzer, H., Lichtner, R. B., Nishino, Y., Parczyk, K., Sauer, G., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh022 · Cited by 87 · see citing works

ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective

Saxena, R., & Dwivedi, A. (2010) · Medicinal Research Reviews · doi:10.1002/med.20209 · Cited by 86 · see citing works

Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD)

Liu, J., Zheng, S., Akerstrom, V. L., Yuan, C., Ma, Y., Zhong, Q., Zhang, C., Zhang, Q., Guo, S., Ma, P., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00753 · Cited by 86 · see citing works

Responses to Pure Antiestrogens (ICI 164384, ICI182780) in Estrogen‐Sensitive and‐Resistant Experimental and Clinical Breast Cancera

Nicholson, R. I., Gee, J. M. W., Manning, D. L., Wakeling, A. E., Montano, M. M., & Katzenellenbogen, B. S. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb31376.x · Cited by 84 · see citing works

Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer

Xiong, R., Zhao, J., Gutgesell, L. M., Wang, Y., Lee, S., Karumudi, B., Zhao, H., Lu, Y., Tonetti, D. A., & Thatcher, G. R. J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01355 · Cited by 83 · see citing works

The development of endocrine therapy for women with breast cancer

Sainsbury, R. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.07.006 · Cited by 78 · see citing works

Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors

Patel, H., Tao, N., Lee, K.-M., Huerta-Rosario, M., Arlt, H., Mullarkey, T. L., Troy, S. M., Arteaga, C. L., & Bihani, T. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1230-0 · Cited by 78 · see citing works

Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927

Kahraman, M., Govek, S. P., Nagasawa, J. Y., Lai, A. G., Bonnefous, C., Douglas, K. L., Sensintaffar, J., Liu, N., Lee, K., Aparicio, A. M., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00414 · Cited by 78 · see citing works

A Good Drug Made Better: The Fulvestrant Dose-Response Story

Robertson, J. F. R., Lindemann, J. P. O., Garnett, S., Anderson, E., Nicholson, R. I., Kuter, I., & Gee, J. M. W. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.06.005 · Cited by 73 · see citing works

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance

Nardone, A., Weir, H. M., Delpuech, O., Brown, H., Angelis, C. D., Cataldo, M. L., Fu, X., Shea, M. J., Mitchell, T., Veeraraghavan, J., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0354-9 · Cited by 68 · see citing works

Selective Estrogen Receptor Modulators with Conformationally Restricted Side Chains. Synthesis and Structure−Activity Relationship of ERα-Selective Tetrahydroisoquinoline Ligands

Renaud, J., Bischoff, S. F., Buhl, T., Floersheim, P., Fournier, B., Geiser, M., Halleux, C. M., Kallen, J. A., Keller, H., & Ramage, P. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040858p · Cited by 67 · see citing works

Full antagonism of the estrogen receptor without a prototypical ligand side chain

Srinivasan, S., Nwachukwu, J. C., Bruno, N. E., Dharmarajan, V., Goswami, D., Kastrati, I., Novick, S. J., Nowak, J., Cavett, V. J., Zhou, H., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2236 · Cited by 66 · see citing works

Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity

Fanning, S. W., Hodges-Gallagher, L., Myles, D. C., Sun, R., Fowler, C. E., Plant, I. N., Green, B. D., Harmon, C. L., Greene, G. L., & Kushner, P. J. (2018) · Nature Communications · doi:10.1038/s41467-018-04413-3 · Cited by 64 · see citing works

Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial

Paoletti, C., Schiavon, G., Dolce, E. M., Darga, E. P., Carr, T. H., Geradts, J., Hoch, M., Klinowska, T. C. M., Lindemann, J. P. O., Marshall, G. B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1569 · Cited by 64 · see citing works

Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer

Shagufta, Ahmad, I., Mathew, S., & Rahman, S. (2020) · RSC Medicinal Chemistry · doi:10.1039/c9md00570f · Cited by 64 · see citing works

Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer

Xiong, R., Patel, H., Gutgesell, L. M., Zhao, J., Delgado-Rivera, L., Pham, T. D., Zhao, H., Carlson, K. E., Martin, T. A., Katzenellenbogen, J. A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01276 · Cited by 63 · see citing works

Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers

Fumagalli, D., Wilson, T. R., Salgado, R., Lu, X., Yu, J., O'Brien, C. L., Walter, K., Huw, L., Criscitiello, C., Laïos, I., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw286 · Cited by 59 · see citing works

New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons

Wang, L., Guillen, V. S., Sharma, N., Flessa, K., Min, J., Carlson, K. E., Toy, W., Braqi, S., Katzenellenbogen, B. S., Katzenellenbogen, J. A., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00106 · Cited by 59 · see citing works

Oestrogen Receptors and Selective Oestrogen Receptor Modulators: Molecular and Cellular Pharmacology

Nilsson, S. V., & Koehler, K. F. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto960103.x · Cited by 57 · see citing works

Characterization of the Pharmacophore Properties of Novel Selective Estrogen Receptor Downregulators (SERDs)

Kieser, K. J., Kim, D. W., Carlson, K. E., Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100047k · Cited by 56 · see citing works

Inactivation of the Pure Antiestrogen Fulvestrant and Other Synthetic Estrogen Molecules by UDP-Glucuronosyltransferase 1A Enzymes Expressed in Breast Tissue

Chouinard, S., Tessier, M., Vernouillet, G., Gauthier, S., Labrie, F., Barbier, O., & Bélanger, A. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.015891 · Cited by 54 · see citing works

Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft

Govek, S. P., Nagasawa, J. Y., Douglas, K. L., Lai, A. G., Kahraman, M., Bonnefous, C., Aparicio, A. M., Darimont, B. D., Grillot, K. L., Joseph, J. D., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.09.074 · Cited by 50 · see citing works

Development of New Estrogen Receptor-Targeting Therapeutic Agents for Tamoxifen-Resistant Breast Cancer

Jiang, Q., Zheng, S., & Wang, G. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.63 · Cited by 48 · see citing works

Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer

Burks, H. E., Abrams, T. J., Kirby, C. A., Baird, J., Fekete, A., Hamann, L. G., Kim, S., Lombardo, F., Loo, A. T., Lubicka, D., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01468 · Cited by 47 · see citing works

Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity

O’Boyle, N. M., Barrett, I., Greene, L. M., Carr, M. J., Fayne, D., Twamley, B., Knox, A. J. S., Keely, N. O., Zisterer, D. M., & Meegan, M. J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01917 · Cited by 47 · see citing works

Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs)

Li, Y., Zhang, S., Zhang, J., Hu, Z., Yuan, X., Huang, J., Dong, C., Huang, S., & Zhou, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.058 · Cited by 47 · see citing works

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer

Andreano, K. J., Wardell, S. E., Baker, J. G., Desautels, T. K., Baldi, R. M., Chao, C., Heetderks, K. A., Bae, Y., Xiong, R., Tonetti, D. A., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05575-9 · Cited by 47 · see citing works

Modulation of nuclear receptor activity by the F domain

Patel, S. R., & Skafar, D. F. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.009 · Cited by 46 · see citing works

Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators

Degorce, S. L., Bailey, A., Callis, R. J., Savi, C. D., Ducray, R., Lamont, G. M., MacFaul, P. A., Maudet, M., Martin, S. W., Morgentin, R., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00066 · Cited by 46 · see citing works

In vitro and in vivo biologic evaluation of long‐circulating biodegradable drug carriers loaded with the pure antiestrogen RU 58668

Ameller, T., Marsaud, V., Legrand, P., Gref, R., & Renoir, J. (2003) · International Journal of Cancer · doi:10.1002/ijc.11248 · Cited by 46 · see citing works

Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer

Lu, Y., Gutgesell, L. M., Xiong, R., Zhao, J., Li, Y., Rosales, C. I., Hollas, M. A. R., Shen, Z., Gordon-Blake, J. M., Dye, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01580 · Cited by 46 · see citing works

Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer

Nagasawa, J. Y., Govek, S. P., Kahraman, M., Lai, A. G., Bonnefous, C., Douglas, K. L., Sensintaffar, J., Lu, N., Lee, K., Aparicio, A. M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00921 · Cited by 44 · see citing works

Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat

Scott, J. S., Bailey, A., Davies, R. D. M., Degorce, S. L., MacFaul, P. A., Gingell, H., Moss, T., Norman, R. A., Pink, J. H., Rabow, A. A., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00413 · Cited by 43 · see citing works

Ligand-Induced Estrogen Receptor α Degradation by the Proteasome: New Actors?

Calligé, M., & Richard‐Foy, H. (2006) · Nuclear Receptor Signaling · doi:10.1621/nrs.04004 · Cited by 43 · see citing works

Rational Design of a Boron-Modified Triphenylethylene (GLL398) as an Oral Selective Estrogen Receptor Downregulator

Liu, J., Zheng, S., Guo, S., Zhang, C., Zhong, Q., Zhang, Q., Ma, P., Skripnikova, E., Bratton, M. R., Wiese, T. E., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00410 · Cited by 42 · see citing works

Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status

Zhong, Q., Zhang, C., Zhang, Q., Miele, L., Zheng, S., & Wang, G. (2015) · BMC Cancer · doi:10.1186/s12885-015-1621-2 · Cited by 42 · see citing works

Discovery of Novel Quinoline-Based Estrogen Receptor Ligands Using Peptide Interaction Profiling

Hoekstra, W. J., Patel, H. S., Liang, X., Blanc, J.-B. E., Heyer, D. O., Willson, T. M., Iannone, M. A., Kadwell, S. H., Miller, L. A., Pearce, K. H., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040154f · Cited by 42 · see citing works

Tricyclic Indazoles—A Novel Class of Selective Estrogen Receptor Degrader Antagonists

Scott, J. S., Bailey, A., Buttar, D., Carbajo, R. J., Curwen, J., Davey, P. R. J., Davies, R. D. M., Degorce, S. L., Donald, C. S., Gangl, E. T., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01837 · Cited by 41 · see citing works

Purification of estradiol receptor by affinity chromatography. Representative experiments

Truong, H., Geynet, C., Millet, C., Soulignac, O., Bucourt, R., VIGNAU, M., TORELLI, V., & Baulieu, É.-É. (1973) · FEBS Letters · doi:10.1016/0014-5793(73)80306-0 · Cited by 40 · see citing works

Bicyclic core estrogens as full antagonists: synthesis, biological evaluation and structure–activity relationships of estrogen receptor ligands based on bridged oxabicyclic core arylsulfonamides

Zhu, M., Zhang, C., Nwachukwu, J. C., Srinivasan, S., Cavett, V. J., Zheng, Y., Carlson, K. E., Dong, C., Katzenellenbogen, J. A., Nettles, K. W., et al. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob26531a · Cited by 38 · see citing works

ERα-associated protein networks

Schultz-Norton, J. R., Ziegler, Y., & Nardulli, A. M. (2011) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.11.005 · Cited by 38 · see citing works

Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer

Zhang, C., Zhong, Q., Zhang, Q., Zheng, S., Miele, L., & Wang, G. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3461-9 · Cited by 38 · see citing works

Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells

Min, J., Guillen, V. S., Sharma, A., Zhao, Y., Ziegler, Y., Gong, P., Mayne, C. G., Srinivasan, S., Kim, S. H., Carlson, K. E., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00585 · Cited by 35 · see citing works

Anti‐breast cancer potential of SS5020, a novel benzopyran antiestrogen

Suzuki, N., Liu, X., Laxmi, Y. R. S., Okamoto, K., Kim, H. J., Zhang, G., Chen, J. J., Okamoto, Y., & Shibutani, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25659 · Cited by 35 · see citing works

Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer

Busonero, C., Leone, S., Bartoloni, S., & Acconcia, F. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.10.020 · Cited by 34 · see citing works

Antiestrogenic activity of two 11β-estradiol derivatives on MCF-7 breast cancer cells

Jin, L. (1995) · Steroids · doi:10.1016/0039-128x(95)00079-6 · Cited by 34 · see citing works

Pure antiestrogen RU 58668—loaded nanospheres: morphology, cell activity and toxicity studies

Ameller, T., Marsaud, V., Legrand, P., Gref, R., & Renoir, J. (2003) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2003.11.002 · Cited by 34 · see citing works

Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer

Liang, J., Blake, R. A., Chang, J. H., Friedman, L. S., Goodacre, S. C., Hartman, S. J., Ingalla, E., Kiefer, J. R., Kleinheinz, T., Labadie, S. S., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00224 · Cited by 33 · see citing works

RU 58668: Further in vitro and in vivo pharmacological data related to its antitumoral activity

Velde, P. V. D., Nique, F., Planchon, P., Prevost, G. P., Brémaud, J., HAMEAU, M., Magnien, V., Philibert, D., & Teutsch, G. (1996) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(96)00140-9 · Cited by 33 · see citing works

Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain

Blizzard, T. A., DiNinno, F. P., Chen, H. Y., Kim, S., Wu, J. Y., CHAN, W. W.-S., Birzin, E. T., Yang, Y. T., Pai, L.-Y., Hayes, E. C., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.05.089 · Cited by 33 · see citing works

Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators

Shoda, T., Kato, M., Harada, R., Fujisato, T., Okuhira, K., Demizu, Y., Inoue, H., Naito, M., & Kurihara, M. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.05.002 · Cited by 32 · see citing works

Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator

Shoda, T., Okuhira, K., Kato, M., Demizu, Y., Inoue, H., Naito, M., & Kurihara, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.11.078 · Cited by 30 · see citing works

Both N- and C-terminal transactivation functions of DNA-bound ERalpha are blocked by a novel synthetic estrogen ligand.

Yamamoto, Y., Wada, O., Takada, I., Yogiashi, Y., Shibata, J., Yanagisawa, J., Kitazato, K., & Kato, S. (2003) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2003.10.178 · Cited by 30 · see citing works

Faslodex (ICI 182780)

Howell, A. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00241-0 · Cited by 30 · see citing works

A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs)

Callis, R. J., Rabow, A. A., Tonge, M. E., Bradbury, R. H., Challinor, M., Roberts, K., Jones, K. L., & Walker, G. E. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115580298 · Cited by 29 · see citing works

Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer

Parl, F. F. (2003) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500201 · Cited by 28 · see citing works

The estrogen receptor alpha nuclear localization sequence is critical for fulvestrant-induced degradation of the receptor

Casa, A. J., Hochbaum, D., Sreekumar, S., Oesterreich, S., & Lee, A. V. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.08.007 · Cited by 26 · see citing works

Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines.

Müller, V., Jensen, E. V., & Knabbe, C. (1998) · PubMed · Cited by 24 · see citing works

Selective Estrogen Receptor Modulator Medicinal Chemistry At Merck. A Review

Blizzard, T. A. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608784535066 · Cited by 23 · see citing works

FULVESTRANT: A REVIEW OF ITS DEVELOPMENT, PRE‐CLINICAL AND CLINICAL DATA

Wardley, A. M. (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11261.x · Cited by 23 · see citing works

Synthesis and structure–activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution

Gauthier, S., Cloutier, J., Dory, Y. L., Favre, A., Mailhot, J., Ouellet, C., Schwerdtfeger, A., Mérand, Y., Martel, C., Simard, J., et al. (2005) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756360500043448 · Cited by 21 · see citing works

Synthesis and evaluation of raloxifene derivatives as a selective estrogen receptor down-regulator

Shoda, T., Kato, M., Fujisato, T., Misawa, T., Demizu, Y., Inoue, H., Naito, M., & Kurihara, M. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.04.068 · Cited by 20 · see citing works

Novel class of 7-Oxabicyclo[2.2.1]heptene sulfonamides with long alkyl chains displaying improved estrogen receptor α degradation activity

Hu, Z., Li, Y., Xie, B., Ning, W., Yuan, X., Huang, Y., Zhao, C., Huang, J., Dong, C., & Zhou, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111605 · Cited by 20 · see citing works

Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels

Yoneya (2009) · Oncology Reports · doi:10.3892/or_00000280 · Cited by 17 · see citing works

TAS-108: A Novel Steroidal Antiestrogen

Buzdar, A. U. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.906s.11.2 · Cited by 17 · see citing works

Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry

Scott, J. S., Breed, J., Carbajo, R. J., Davey, P. R. J., Greenwood, R. D. R., Huynh, H. K., Klinowska, T. C. M., Morrow, C. J., Moss, T. A., Polański, R., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00370 · Cited by 16 · see citing works

Anti‐breast cancer potential of SS1020, a novel antiestrogen lacking estrogenic and genotoxic actions

Laxmi, Y. R. S., Liu, X., Suzuki, N., Kim, S. Y., Okamoto, K., Kim, H. J., Zhang, G., Chen, J. J., Okamoto, Y., & Shibutani, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25167 · Cited by 14 · see citing works

Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927

Labadie, S. S., Li, J., Blake, R. A., Chang, J. H., Goodacre, S. C., Hartman, S. J., Liang, W., Kiefer, J. R., Kleinheinz, T., Lai, T., et al. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.07.013 · Cited by 14 · see citing works

Parameters influencing the purification of calf uterus estrogen ‘receptor’ by affinity chromatography

Truong, H., & Baulieu, É.-É. (1974) · FEBS Letters · doi:10.1016/0014-5793(74)80397-2 · Cited by 12 · see citing works

Identification of a novel, orally bioavailable estrogen receptor downregulator

Yoneya, T., Taniguchi, K., Tsunenari, T., Saito, H., Kanbe, Y., Morikawa, K., & Yamada‐Okabe, H. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000171515.27439.de · Cited by 10 · see citing works

Randomized phase II study of three doses of oral TAS ‐108 in postmenopausal patients with metastatic breast cancer

Inaji, H., Iwata, H., Nakayama, T., Yamamoto, N., Sato, Y., Tokuda, Y., Aogi, K., Saji, S., Watanabe, K., Saito, T., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02354.x · Cited by 8 · see citing works

Randomized double‐blind phase 2 trial of 3 doses of TAS‐108 in patients with advanced or metastatic postmenopausal breast cancer

Buzdar, A. U., Vogel, C., Schwartzberg, L. S., Garin, A. M., Perez, A., Ingle, J. N., Houghton, M., Zergebel, C., & Kimball, B. (2011) · Cancer · doi:10.1002/cncr.26419 · Cited by 6 · see citing works

Overcoming Cancer Drug Resistance Utilizing PROTAC Technology

Burke, M. R., Smith, A. R., & Zheng, G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.872729 · Cited by 126 · see citing works

Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges

Rej, R. K., Thomas, J. E., Acharyya, R. K., Rae, J. M., & Wang, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00136 · Cited by 115 · see citing works

Targeting Breast Cancer: An Overlook on Current Strategies

Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M., & Catalano, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043643 · Cited by 88 · see citing works

Accelerating drug development in breast cancer: New frontiers for ER inhibition

Ferraro, E., Walsh, E. M., Tao, J. J., Chandarlapaty, S., & Jhaveri, K. L. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102432 · Cited by 57 · see citing works

Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity

Chen, Z., Hu, B., Rej, R. K., Wu, D., Acharyya, R. K., Wang, M., Xu, T., Lü, J., Metwally, H., Wang, Y., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01186 · Cited by 52 · see citing works

Development of PROTAC Degrader Drugs for Cancer

Vetma, V., O’Connor, S., & Ciulli, A. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061824-105806 · Cited by 53 · see citing works

Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer

Neupane, N., Bawek, S. J., Gurusinghe, S., Ghaffary, E. M., Mirmosayyeb, O., Thapa, S., Falkson, C. I., O’Regan, R. M., & Dhakal, A. (2024) · Cancers · doi:10.3390/cancers16030619 · Cited by 50 · see citing works

Design, 3D-QSAR, molecular docking, ADMET, molecular dynamics and MM-PBSA simulations for new anti-breast cancer agents

Rhabori, S. E., Alaqarbeh, M., Aissouq, A. E., Bouachrıne, M., Chtita, S., & Khalil, F. (2024) · Chemical Physics Impact · doi:10.1016/j.chphi.2023.100455 · Cited by 45 · see citing works

Cancer Cell‐Specific Fluorescent Prodrug Delivery Platforms

Ma, S.-Y., Kim, J. H., Chen, W., Li, L., Lee, J., Xue, J., Liu, Y., Chen, G., Tang, B., Tao, W., et al. (2023) · Advancement of science · doi:10.1002/advs.202207768 · Cited by 36 · see citing works

Discovery of Novel Bicyclic Phenylselenyl-Containing Hybrids: An Orally Bioavailable, Potential, and Multiacting Class of Estrogen Receptor Modulators against Endocrine-Resistant Breast Cancer

Deng, X., Xie, B., Li, Q., Xiao, Y., Hu, Z., Deng, X., Fang, P., Dong, C., Zhou, H.-B., & Huang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00525 · Cited by 43 · see citing works

Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer

Guglielmi, G., Re, M. D., Gol, L. S., Bengala, C., Danesi, R., & Fogli, S. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176424 · Cited by 40 · see citing works

Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer <i>In Vitro</i> and <i>In Vivo</i>

Xie, B., Yin, Z., Hu, Z., Lv, J., Du, C., Deng, X., Huang, Y., Li, Q., Huang, J., Liang, K., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02032 · Cited by 39 · see citing works

Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer

Xin, L., Wang, C., Cheng, Y., Wang, H., Guo, X., Deng, X., Deng, X., Xie, B., Hu, H., Min, C., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00196 · Cited by 38 · see citing works

From Pure Antagonists to Pure Degraders of the Estrogen Receptor: Evolving Strategies for the Same Target

Mottamal, M., Kang, B.-R., Peng, X., & Wang, G. (2021) · ACS Omega · doi:10.1021/acsomega.0c06362 · Cited by 37 · see citing works

SERD-NHC-Au(I) complexes for dual targeting ER and TrxR to induce ICD in breast cancer

Lu, Y., Sheng, X., Liu, C., Liang, Z., Wang, X., Liu, L., Wen, Z., Yang, Z., Du, Q., & Liu, W. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106731 · Cited by 37 · see citing works

Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview

Bhatia, N. S., Hazra, S., & Thareja, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115422 · Cited by 35 · see citing works

The G Protein-Coupled Estrogen Receptor (GPER): A Critical Therapeutic Target for Cancer

Hall, K. A., & Filardo, E. J. (2023) · Cells · doi:10.3390/cells12202460 · Cited by 30 · see citing works

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer

Bardia, A., Cortés, J., Hurvitz, S. A., Delaloge, S., Iwata, H., Shao, Z., Kanagavel, D., Cohen, P., Liu, Q., Cartot‐Cotton, S., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221083956 · Cited by 31 · see citing works

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination

Ma, C. X., Suman, V. J., Sanati, S., Vij, K. R., Anurag, M., Leitch, A. M., Unzeitig, G. W., Hoog, J., Fernández-Martínez, A., Fan, C., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.6038 · Cited by 28 · see citing works

Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer

Wang, Y., Min, J., Deng, X., Feng, T., Hu, H., Guo, X., Cheng, Y., Xie, B., Yang, Y., Chen, C.-C., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.005 · Cited by 28 · see citing works

Discovery of estrogen receptor α targeting caged hypoxia-responsive PROTACs with an inherent bicyclic skeleton for breast cancer treatment

Xie, B., Xu, B., Xin, L., Wei, Y., Guo, X., & Dong, C. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106590 · Cited by 27 · see citing works

Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Jhaveri, K. L., Bellet, M., Turner, N. C., Loi, S., Bardia, A., Boni, V., Sohn, J., Neilan, T. G., Villanueva-Vázquez, R., Kabos, P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1796 · Cited by 27 · see citing works

Elacestrant: a new FDA-approved SERD for the treatment of breast cancer

Bhatia, N., & Thareja, S. (2023) · Medical Oncology · doi:10.1007/s12032-023-02045-2 · Cited by 27 · see citing works

Identification of Novel Dual-Target Estrogen Receptor α Degraders with Tubulin Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer

Deng, X., Deng, X., Ning, W., Xin, L., Li, Q., Hu, Z., Xie, B., Liang, K., Min, C., Dong, C., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00465 · Cited by 26 · see citing works

Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer

Luo, G., Lin, X., Ren, S., Wu, S., Wang, X., Ma, L., & Xiang, H. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113870 · Cited by 25 · see citing works

Selective Estrogen Receptor Modulators (SERMs) for the treatment of ER+ breast cancer: An overview

Das, S., Kulkarni, S., Singh, Y., Kumar, P., & Thareja, S. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133853 · Cited by 25 · see citing works

Targeting the crosstalk between estrogen receptors and membrane growth factor receptors in breast cancer treatment: Advances and opportunities

Yan, S., Ji, J., Zhang, Z., Imam, M., Chen, H., Zhang, D., & Wang, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116615 · Cited by 24 · see citing works

Update on the Role of Neuropeptide Y and Other Related Factors in Breast Cancer and Osteoporosis

Lin, S., Li, Y., Sun, X., Chen, Q., Huang, S., Lin, S., & Cai, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.705499 · Cited by 24 · see citing works

Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha

Jiang, S., Liu, K., Jiang, T., Li, H., Wei, X., Wan, X., Zhong, C., Gong, R., Chen, Z., Zou, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62288-7 · Cited by 23 · see citing works

Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer

Acharyya, R. K., Rej, R. K., Hu, B., Chen, Z., Wu, D., Lü, J., Metwally, H., McEachern, D., Wang, Y., Jiang, W., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01521 · Cited by 23 · see citing works

Research Progress on Bioactive Metal Complexes against ER-Positive Advanced Breast Cancer

Liang, Z., Liu, L., Zhou, Y., Liu, W., & Lu, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01458 · Cited by 23 · see citing works

Ring systems in medicinal chemistry: A cheminformatics analysis of ring popularity in drug discovery over time

Ertl, P., Altmann, E., & Wilcken, R. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118178 · Cited by 22 · see citing works

Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models

Michmerhuizen, A. R., Lerner, L. M., Pesch, A. M., Ward, C., Schwartz, R. L., Wilder-Romans, K., Liu, M., Nino, C. A., Jungles, K. M., Azaria, R. D., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00397-y · Cited by 22 · see citing works

The current landscape of aromatase inhibitors for the treatment of estrogen receptor-positive breast carcinoma

Bhutani, K., Vishwakarma, S., Yadav, P., & Yadav, M. K. (2025) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2025.106729 · Cited by 20 · see citing works

A high-throughput platform for single-molecule tracking identifies drug interaction and cellular mechanisms

McSwiggen, D. T., Liu, H., Tan, R., Puig, S. A., Akella, L. B., Berman, R., Bretan, M., Chen, H., Darzacq, X., Ford, K., et al. (2024) · eLife · doi:10.7554/elife.93183.3 · Cited by 18 · see citing works

Integrative strategies in breast cancer therapy: Conventional approaches, emerging advances, and future challenges

Eapen, J. V., George, P. R., Thomas, S., & Antony, J. (2025) · ASPET Discovery · doi:10.1016/j.aspetd.2025.100012 · Cited by 14 · see citing works

Human Estrogen Receptor Alpha Antagonists, Part 3: 3-D Pharmacophore and 3-D QSAR Guided Brefeldin A Hit-to-Lead Optimization toward New Breast Cancer Suppressants

Kurtanović, N., Tomašević, N., Matić, S. L., Proia, E., Sabatino, M., Antonini, L., Mladenović, M. P., & Ragno, R. (2022) · Molecules · doi:10.3390/molecules27092823 · Cited by 14 · see citing works

The discovery of potent USP2/USP8 dual-target inhibitors for the treatment of breast cancer via structure guided optimization of ML364

Tian, Y., Liu, K., Wu, D., Wu, L., Xu, Q., Wei, W., Li, Z., Du, Q., & Bian, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116275 · Cited by 14 · see citing works

Next generation selective estrogen receptor degraders in postmenopausal women with advanced-stage hormone receptors-positive, HER2-negative breast cancer

Sharaf, B., Hajahjeh, A., Hani, H. B., & Abdel‐Razeq, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1385577 · Cited by 14 · see citing works

Emerging Roles of RNF168 in Tumor Progression

Xie, T., Qin, H., Yuan, Z., Zhang, Y., Li, X., & Zheng, L. (2023) · Molecules · doi:10.3390/molecules28031417 · Cited by 14 · see citing works

Advancing precision oncology in breast cancer: the FDA approval of elacestrant and guardant 360CDx: a correspondence

Abbasi, H. Q., Adeena, M., Khan, A. M., Shahnoor, S., Oduoye, M. O., & Nafula, W. P. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000334 · Cited by 13 · see citing works

Dual-targeting of the aromatase binding domain of heme and androstenedione by Pt( iv ) prodrugs: a new treatment for postmenopausal breast cancer

Liu, X.-M., Li, Z., He, X.-R., Liu, R.-P., Ma, Z., Qiao, X., Wang, S., & Xu, J. (2022) · Inorganic Chemistry Frontiers · doi:10.1039/d2qi00900e · Cited by 12 · see citing works

The Tetramethylpyrazine Derivative Statmp-151: A Novel Small Molecule Stat3 Inhibitor With Promising Activity Against Breast Cancer

Chen, F., Wang, Y., Huang, H., Li, W., Ma, J., Yao, D., Tang, Z.-J., Xue, T., Ha, L., Ren, Y., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.651976 · Cited by 12 · see citing works

Intercepting the Downstream of the Estrogen Receptor Signaling Pathway: Discovery of a Potent and Efficient SRC-3 PROTAC Degrader for Overcoming Endocrine Resistance Breast Cancer

Liang, J., Wang, D., Wu, Y., Shi, J., Xie, B., Xiao, R., Ni, J., Wang, C., Dong, C., Shu, H., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00425 · Cited by 11 · see citing works

Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer

Lu, Y., Liu, C., Wang, X., Liu, L., Zhao, Z., Liang, Z., Liu, W., Wen, Z., Du, Q., & Liu, W. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115324 · Cited by 11 · see citing works

Discovery of highly potent proapoptotic antiestrogens in a series of androst-5,16-dienes D-modified with imidazole-annulated pendants

Birukova, V. E., Scherbakov, A. M., Ilina, A. A., Salnikova, D. I., Andreeva, O. E., Dzichenka, Y. U., Zavarzin, I. V., & Volkova, Y. A. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106309 · Cited by 11 · see citing works

Human estrogen receptor α antagonists, part 2: Synthesis driven by rational design, in vitro antiproliferative, and in vivo anticancer evaluation of innovative coumarin-related antiestrogens as breast cancer suppressants

Kurtanović, N., Stanković, N., Matić, S. L., Mitrović, M. M., Kostić, D. A., Sabatino, M., Antonini, L., Ragno, R., & Mladenović, M. P. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113869 · Cited by 11 · see citing works

A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway

Zhou, J., Shen, R., Liu, J., Deng, X., Xin, L., Zhou, H., & Huang, J. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117235 · Cited by 9 · see citing works

Human Estrogen Receptor α Antagonists. Part 1: 3-D QSAR-Driven Rational Design of Innovative Coumarin-Related Antiestrogens as Breast Cancer Suppressants through Structure-Based and Ligand-Based Studies

Mihović, N., Stanković, N., Matić, S. L., Mitrović, M. M., Kostić, D. A., Sabatino, M., Antonini, L., Ragno, R., & Mladenović, M. P. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00530 · Cited by 9 · see citing works

A high-throughput platform for single-molecule tracking identifies drug interaction and cellular mechanismsPreprint

McSwiggen, D. T., Liu, H., Tan, R., Puig, S. A., Akella, L. B., Berman, R., Bretan, M., Chen, H., Darzacq, X., Ford, K., et al. (2023) · eLife · doi:10.7554/elife.93183 · Cited by 9 · see citing works

Discovery of novel quinoline scaffold selective estrogen receptor degraders (SERDs) for treatment of ER positive breast cancer with enhanced antiproliferative bioactivity through immunogenic cell death (ICD) effects

Lu, Y., Liang, Z., Liu, L., Zhou, Y., Liu, C., Zhao, Z., Zheng, T., Du, Q., & Liu, W. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116534 · Cited by 8 · see citing works

The anti-aromatase and anti-estrogenic activity of plant products in the treatment of estrogen receptor-positive breast cancer

Verhoog, N. J. D., & Spies, L.-M. L. (2024) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2024.106581 · Cited by 8 · see citing works

Low levels of sex hormone-binding globulin predict an increased breast cancer risk and its underlying molecular mechanisms

Zhao, S., Gu, J., Tian, Y., Wang, R., & Li, W. (2024) · Open Life Sciences · doi:10.1515/biol-2022-0822 · Cited by 7 · see citing works

Discovery of Thiochroman Derivatives as Potent, Oral Selective Estrogen Receptor Degraders and Antagonists for the Treatment of Endocrine-Resistant Breast Cancer

Zhang, D., Lu, Z., He, Y., Leng, X.-Y., Meng, X., Lei, X., Kong, D., Sun, L., Hu, W., & Yang, Y. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02453 · Cited by 7 · see citing works

Disposition and Absolute Bioavailability of Oral Imlunestrant in Healthy Women: A Phase 1, Open‐Label Study

Datta‐Mannan, A., Czeskis, B. A., Shanks, E., Yuen, E., Hall, S. D., Cruz, V. R., & Cassidy, K. C. (2025) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1562 · Cited by 6 · see citing works

Post-CDK4/6 inhibitor treatment landscape in metastatic hormone receptor-positive breast cancer: a narrative review

Güren, A. K., Kırcalı, M. F., Köstek, O., & Demircan, N. C. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2593540 · Cited by 6 · see citing works

New Zosteropenillines and Pallidopenillines from the Seagrass-Derived Fungus Penicillium yezoense KMM 4679

Leshchenko, E. V., Chingizova, E. A., Antonov, A. S., Shlyk, N. P., Borkunov, G. V., Berdyshev, D. V., Chausova, V. E., Kirichuk, N. N., Khudyakova, Y. V., Chingizov, A. R., et al. (2024) · Marine Drugs · doi:10.3390/md22070317 · Cited by 6 · see citing works

Pd-Catalyzed Cross-Coupling of Cyclopropanols with 2-Br-p-Quinone Methides/2-Br-Cinnamate Esters Followed by a 1,6- and 1,4-Conjugate Addition Reaction

Mane, B. B., Savekar, A. T., & Waghmode, S. B. (2025) · Organic Letters · doi:10.1021/acs.orglett.5c00092 · Cited by 6 · see citing works

OBHS impairs the viability of breast cancer via decreasing ERα and Atg13

Zhou, J., Shen, R., Zhou, H., & Huang, J. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.08.013 · Cited by 6 · see citing works

Exploring TMPRSS2 Drug Target to Combat Influenza and Coronavirus Infection

Baby, K., Vithalkar, M. P., Dastidar, S. G., Mukhopadhyay, C., Hamdy, R. M., Soliman, S. S. M., & Nayak, Y. (2025) · Scientifica · doi:10.1155/sci5/3687892 · Cited by 5 · see citing works

Sustainable ionic liquid design for enhanced solubility and safety of Tamoxifen: A computational exploration

Zheng, D., Jiang, S. H., Qin, S., An, B., & Gao, L. (2025) · Sustainable Chemistry and Pharmacy · doi:10.1016/j.scp.2025.102046 · Cited by 5 · see citing works

Structure–Activity Relationships of Triphenylethylene Derivatives and Their Evaluation as Anticancer and Antiviral Agents

Ahmed, N. S., El-Nakib, H. E., Ramsis, M. M., Albably, N. O., Wober, J., Weigand, J. J., Schwedtmann, K., Zierau, O., & Abadi, A. (2023) · ACS Omega · doi:10.1021/acsomega.3c01682 · Cited by 5 · see citing works

Discovery of non-antiproliferative selective estrogen receptor degraders (SERDs) based on scaffold optimization of elacestrant

Lu, Y., Zhao, Z., Wang, S., Zheng, T., Chen, X., Liu, L., Zhu, Y., & Liu, W. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116897 · Cited by 5 · see citing works

Novel 11β-substituted estradiol conjugates: Transition from ERα agonizts to effective PROTAC degraders

Luo, G., Li, X., Lin, X., Lu, X., Li, Z., & Xiang, H. (2022) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2022.106154 · Cited by 5 · see citing works

Cyclopia extracts act as selective estrogen receptor subtype downregulators in estrogen receptor positive breast cancer cell lines: Comparison to standard of care breast cancer endocrine therapies and a selective estrogen receptor agonist and antagonist

Olayoku, F. R., Verhoog, N. J. D., & Louw, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1122031 · Cited by 5 · see citing works

A high-throughput platform for single-molecule tracking identifies drug interaction and cellular mechanismsPreprint

McSwiggen, D. T., Liu, H., Tan, R., Puig, S. A., Akella, L. B., Berman, R., Bretan, M., Chen, H., Darzacq, X., Ford, K., et al. (2024) · eLife · doi:10.7554/elife.93183.2 · Cited by 5 · see citing works

Comprehensive analysis of Crotalaria willdenowiana DC.: GC–MS profiling, antioxidant and anticancer activities, molecular docking studies, and in silico ADME profiling

Muthukrishnan, S., Raman, C., Chandrasekaran, G., Soundhirapandi, P., Chinnappan, G., Prakasam, R., Manogar, P., & Pandiyan, J. (2025) · 3 Biotech · doi:10.1007/s13205-025-04409-z · Cited by 4 · see citing works

Treatment of ER-positive breast cancer with FDA-approved aromatase inhibitors

Kim, N., & Lukong, K. E. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101134 · Cited by 4 · see citing works

Secondary metabolites of Vietnamese marine fungus Penicillium chermesinum 2104NT-1.3 and their cardioprotective activity

Ngoc, N. T. D., Yurchenko, E. A., Trinh, P. T. H., Menchinskaya, E. S., Trang, V. T. D., Savagina, A. D., Минин, А. С., Thinh, P. D., Khánh, H. H. N., Vân, T. T. T., et al. (2024) · Regional Studies in Marine Science · doi:10.1016/j.rsma.2024.104003 · Cited by 4 · see citing works

Artificial Protein Crosstalk with a Molecule that Exchanges Binding Partners

Suss, O., Halfin, O., Porat, Z., Sirkis, Y. F., Motiei, L., & Margulies, D. H. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202312461 · Cited by 4 · see citing works

A high-throughput platform for single-molecule tracking identifies drug interaction and cellular mechanismsPreprint

McSwiggen, D. T., Liu, H., Tan, R., Puig, S. A., Akella, L. B., Berman, R., Bretan, M., Chen, H., Darzacq, X., Ford, K., et al. (2023) · eLife · doi:10.7554/elife.93183.1 · Cited by 4 · see citing works

Artificial Intelligence (AI)-Assisted Treatment of Breast Cancer

Mubasshira, Rahman, M. M., Mondal, J., Parvez, M. M. H., Uddin, M. N., & Akter, L. (2026) · Springer eBooks · doi:10.1007/978-981-95-3682-5_18 · Cited by 5 · see citing works

Analysis of the Main Directions in the Development of Mono and Combination Pharmacotherapy Acting on Hormonal Signaling Pathways of Breast Cancer According to the FDA Databases and Clinicaltrials.gov

Abdullaeva, S., Abdullaeva, P., Gabdrakhimova, R. A., Александровна, Н. К., Евгеньевна, Н. М., Liu, J., MIu, S., Самородов, А. В., Smolyarchuk, Е. А., Sukocheva, O. A., et al. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673345472250301052255 · Cited by 3 · see citing works

A comprehensive overview on mononuclear and multinuclear Ruthenium-based coordination compounds as breast cancer therapeutics

Naseem, M., Siddique, A., Latif, M. S., Alshammari, A. Q., Sheikh, T. A., Alshammari, A. Q., Akhtar, M. N., & Rahman, M. M. (2025) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2025.114718 · Cited by 3 · see citing works

Design, synthesis, molecular modeling, and bioactivity evaluation of 1,10-phenanthroline and prodigiosin (Ps) derivatives and their Copper(I) complexes against mTOR and HDAC enzymes as highly potent and effective new anticancer therapeutic drugs

Çetin, M. M., Peng, W., Unruh, D. K., Mayer, M. F., Mechref, Y. S., & Yelekçi, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.980479 · Cited by 3 · see citing works

Structure–Activity Relationship Study of Tris-Benzamides as Estrogen Receptor Coregulator Binding Modulators

Lee, T.-K., Kassees, K., Chen, C., Viswanadhapalli, S., Parra, K., Vadlamudi, R. K., & Ahn, J. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00125 · Cited by 3 · see citing works

Docking Study, ADMET Profiling of the Designed 3-Chlorobenzo[b]thiophene-2-Carbonyl Chloride Derivatives: Promising Anti-Breast Cancer Activity

Al-Owaidi, M. F., & Ameri, M. F. A. (2023) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2023.00152 · Cited by 3 · see citing works

F-α-DDB-derivative, a novel synthetic of bifendate, plus epirubicin improves antitumor efficacy against triple negative breast cancer without additional cardiotoxicity

Huang, H.-Y., Lin, L. Z. Y., Lu, X., & Jiang, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-02545-9 · Cited by 2 · see citing works

Highly potent and selective degrader targeting ERα to improve the treatment outcomes of breast cancer

Bao, X., Yin, X., Xǔ, J., Zhu, Z., Lu, W., Cai, Y., Dai, R., Zheng, Z., Xu, W., Mei, S., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118199 · Cited by 2 · see citing works

Design, Synthesis, and In Vitro Mitotic Evaluation of 3‐Amino‐Isoquinolinones as Anticancer Agents

Abrams, J. N. (2022) · ChemistrySelect · doi:10.1002/slct.202202861 · Cited by 1 · see citing works

Drug discovery of N-methyl-pyrazole derivatives as potent selective estrogen receptor degrader (SERD) for the treatment of breast cancer

Dai, R., Bao, X., Liu, C., Yin, X., Zhu, Z., Zheng, Z., Wang, B., Yang, K., Wen, H., Li, W., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116894 · Cited by 1 · see citing works

Development of Fluorescent Estrogen Receptor Ligands with pH Sensor Functionality

Hirano, T., Yasuda, D., Yamada, T., & Kagechika, H. (2025) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c24-00685 · Cited by 1 · see citing works

Structural evolution progress of orally bioavailable selective estrogen receptor degraders

Zhang, J., Zhang, J., Zhao, Y. Y., Liu, Y., Sun, Y., Lei, H., & Zhai, X. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118288 · Cited by 1 · see citing works

Stability of Steroid Hormone Receptors

Gale-Day, Z. J., & Gestwicki, J. E. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch2

A concise review on breast cancer in pregnancy

Yuvaraj, K., Govindhan, E., Francis Kevin Raj, S., Pavithra, J., & Muralidharan, P. (2023) · International Journal of Science and Research Archive · doi:10.30574/ijsra.2023.8.2.0272 · Cited by 1 · see citing works

Selenium Analogue of LSZ102 as a Highly Potent ER‐α Binder

Paegle, E., & Arsenyan, P. (2023) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202300460

Selenium analogues of rintodestrant (G1T48) as potent estrogen receptor modulators and downregulators

Paegle, E., Dimitrijevs, P., & Arsenyan, P. (2023) · New Journal of Chemistry · doi:10.1039/d3nj01739g

Artificial Protein Crosstalk with a Molecule that Exchanges Binding Partners

Suss, O., Halfin, O., Porat, Z., Sirkis, Y. F., Motiei, L., & Margulies, D. H. (2023) · Angewandte Chemie · doi:10.1002/ange.202312461

Data from Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Jhaveri, K. L., Bellet, M., Turner, N. C., Loi, S., Bardia, A., Boni, V., Sohn, J., Neilan, T. G., Villanueva-Vázquez, R., Kabos, P., et al. (2024) · doi:10.1158/1078-0432.c.7077719

Data from Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Jhaveri, K. L., Bellet, M., Turner, N. C., Loi, S., Bardia, A., Boni, V., Sohn, J., Neilan, T. G., Villanueva-Vázquez, R., Kabos, P., et al. (2024) · doi:10.1158/1078-0432.c.7077719.v1

Design and Structural Investigation of a Series of Prodigiosin and 1,10-Phenanthroline Derivatives as Novel and Highly Potent Anticancer Therapeutic Drugs or Active Pharmaceutical Ingredients

Çetin, M. M., & GÜL, S. B. (2024) · Karadeniz Fen Bilimleri Dergisi · doi:10.31466/kfbd.1423254

Effect of Tasurgratinib as an Orally Available FGFR1–3 Inhibitor on Resistance to a CDK4/6 Inhibitor and Endocrine Therapy in ER+/HER2− Breast Cancer Preclinical Models

Kawano, S., Fukushima, S., Nishibata, K., Gejima, R., & Miyano, S. W. (2025) · Cancers · doi:10.3390/cancers17071084

The Review of Chemistry, Pharmacological properties and Bio-analytical Methods of Oral selective Estrogen Receptor Degrader: Elacestrant

Vyas, A. J., Ramani, A., & Patel, A. I. (2025) · Asian Journal of Pharmaceutical Analysis · doi:10.52711/2231-5675.2025.00011

Identification of novel selective estrogen receptor degraders (SERD) via physics-based and deep-learning-based virtual screening and Bioassys

Chen, M., Zhang, H., Chen, S., Liang, P., Wu, Z., Gao, X., Chen, J., Wu, S., Zhang, J., & Tian, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109011

The degradation revolution: harnessing targeted protein degradation for the treatment of human diseases

Tong, J., Wang, P., Ma, S., Li, J., Zhan, Y., Liu, M., Jin, F., Qu, G., Zheng, C., Wang, X., et al. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06132-1

Developing orally active estrogen receptor degraders by conjugation of boronic tamoxifen and cereblon ligands

Peng, X., Hossain, A., Ma, P., Guo, S., Mottamal, M., Zhang, C., 郑时龙, Kang, B., & Wang, G. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118956

Oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancer title

Etessami, J. D., Valenza, C., Giachetti, P. P. M. B., Crimini, E., Ferraro, E., Marra, A., Belli, C., Minchella, I., Zagami, P., Curigliano, G., et al. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2678481

Novel 10‐Alkoxy 1,4‐Dien‐3‐One Estranes as Multitarget Anticancer Agents Against Estrogen‐Positive Breast Cancer

Kuzminac, I. Z., Bekić, S. S., Stevanović, M. Z., Scholda, J., Kopp, F. B., Petri, E. T., Ćelić, A. S., & Sakač, M. N. (2026) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70321

Evaluating the investigational drug landscape for ESR1 -mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer

Kroemer, M., Lopez, M., Mansi, L., & Curtit, E. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2686701

NCP07: A potent ERα CBS-targeted degrader with dual-action against ESR1 mutations in breast cancer

Liang, J., Wu, Y., Yang, L., Xu, B., Wang, D., Shu, H., Dong, C., Li, S., & Zhou, H. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119113

Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective

Hernándo, C., Ortega-Morillo, B., Tapia, M., Moragón, S., Martínez, M. T., Eroles, P., Garrido‐Cano, I., Adam‐Artigues, A., Lluch, A. M., Bermejo, B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157812 · Cited by 139 · see citing works

Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status

Downton, T. D., Zhou, F. H., Segara, D., Jeselsohn, R. M., & Lim, E. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s380925 · Cited by 68 · see citing works

Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer

Guglielmi, G., Re, M. D., Gol, L. S., Bengala, C., Danesi, R., & Fogli, S. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176424 · Cited by 40 · see citing works

Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice?

Ferro, A., Generali, D., Caffo, O., Caldara, A., Lisi, D. D., Dipasquale, M., Lorenzi, M., Monteverdi, S., Fedele, P., & Ciribilli, Y. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.08.002 · Cited by 9 · see citing works

Selective Estrogen Receptor Degraders (SERDs)

Taylor, M., Kahn, A. M., & Foldi, J. (2024) · Current Breast Cancer Reports · doi:10.1007/s12609-024-00563-0 · Cited by 3 · see citing works